Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Retained Earnings (2016 - 2025)

Marimed (MRMD) has disclosed Retained Earnings for 15 consecutive years, with -$127.9 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 12.77% to -$127.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$127.9 million through Dec 2025, down 12.77% year-over-year, with the annual reading at -$127.9 million for FY2025, 12.77% down from the prior year.
  • Retained Earnings for Q4 2025 was -$127.9 million at Marimed, down from -$123.3 million in the prior quarter.
  • The five-year high for Retained Earnings was -$83.9 million in Q4 2022, with the low at -$127.9 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$100.4 million, with a median of -$98.7 million recorded in 2021.
  • The sharpest move saw Retained Earnings increased 16.42% in 2021, then decreased 20.32% in 2024.
  • Over 5 years, Retained Earnings stood at -$97.4 million in 2021, then increased by 13.83% to -$83.9 million in 2022, then dropped by 19.1% to -$100.0 million in 2023, then decreased by 13.5% to -$113.4 million in 2024, then fell by 12.77% to -$127.9 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$127.9 million, -$123.3 million, and -$118.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.